The cumulative risk of adenomas and advanced adenomas in MSH2 carriers is higher than in MLH1 carriers under colonoscopy surveillance, whereas there is no difference in the cumulative incidence of CRC between the two37. This evidence concerns the gene MSH2 and colorectal carcinoma.